WT13-12, a novel antibacterial for combatting drug resistant bacteria.

AFFILIATION:   Wintermute Biomedical, Missoula, Montana, United States


Track: Medical & Biotech
Area: Infectious Disease
Tech Readiness: TRL 5

Tech Brief: WT13-12 is a completely novel therapy for skin and wound applications that rapidly eradicates drug resistant bacteria including MRSA and carbapenem resistant Enterobacteriaceae (CRE). Furthermore, it speeds wound healing through enhanced tissue regeneration resulting in the accelerated healing of wounds and infection prevention/eradication.


Value Proposition: CNN recently reported that antibiotic resistant bacteria dubbed 'Superbugs' will kill one person every 3 seconds by the year 2050. Currently, they are responsible for 700,000 deaths annually, by 2050, they will kill more humans than cancer. WT13-12 represents a novel antibacterial therapy that will drastically reduce battlefield and hospital infection rates. Investing in this technology will lead to a powerful therapy that can be employed in any environment to stop infection from drug resistant bacteria and enhance wound healing. Employing this technology will enhance the health and safety of warfighters and civilians. We are currently 11 months away from clinical trials. Obtaining the necessary funding of $3M would allow us to complete the IND with the FDA and begin clinical trials. Investing in this project will push forward a therapy that has incredible potency against a broad spectrum of antibiotic resistant bacteria. This drug will make US soldiers safer and better prepared to fight healthy.


Org Type: Mid-stage Startup (A or B)
Booth Number: T317